Unicycive Therapeutics Inc.
13F holders, Q1 2025 (March 31)29holders −2
4new positions
6sold out
$0.57avg. 13F price*
At the end of Q1 2025, 29 institutions reported holding Unicycive Therapeutics Inc. in their 13F filings, down 2 from Q4 2024. 4 opened new positions and 6 sold out. The largest holders were Vivo Capital, LLC ($6.5M), Great Point Partners LLC ($6.3M) and Octagon Capital Advisors LP ($5.7M).
- Company
- Unicycive Therapeutics Inc.
- CUSIP
- 90466Y103
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $56K |
| Exits | 6 | $1.2M |
All 13F filers, Q4 2024 → Q1 2025: 1,768,260 shares bought and 3,542,374 shares sold, net −1,774,114 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 29 holders
| Vivo Capital, LLC | 0.87% | Add +14.0% | 11,370,152 | $6.5M |
| Great Point Partners LLC | 3.43% | No change | 10,980,000 | $6.3M |
| Octagon Capital Advisors LP | 1.25% | No change | 10,000,000 | $5.7M |
| Nantahala Capital Management, LLC | 0.45% | Reduce -9.6% | 9,391,994 | $5.4M |
| Logos Global Management LP | 0.52% | No change | 5,078,927 | $2.9M |
| Walleye Capital LLC | 0.03% | Reduce -18.1% | 4,094,256 | $2.4M |
| Silverarc Capital Management, LLC | 0.29% | Reduce -2.9% | 2,413,489 | $1.4M |
| Acuta Capital Partners, LLC | 1.57% | Add +2.2% | 2,352,887 | $1.4M |
| Alyeska Investment Group, L.P. | 0.00% | No change | 1,750,000 | $1.0M |
| Vanguard Group Inc. | 0.00% | Add +6.5% | 1,212,441 | $697K |
| Geode Capital Management, LLC | 0.00% | Add +10.4% | 579,202 | $333K |
| State Street Corp. | 0.00% | No change | 125,236 | $72K |
| XTX Topco Ltd | 0.00% | Reduce -28.1% | 123,233 | $71K |
| Northern Trust Corp. | 0.00% | Add +85.4% | 107,850 | $62K |
| BlackRock, Inc. | 0.00% | Add +15.2% | 83,242 | $48K |
| Goldman Sachs Group Inc. | 0.00% | Reduce -0.2% | 73,475 | $42K |
| Virtu Financial LLC | 0.00% | New | 38,868 | $22K |
| Cantor Fitzgerald, L. P. | 0.00% | New | 32,971 | $19K |
| Creative Planning | 0.00% | Add +14.3% | 25,910 | $15K |
| Morgan Stanley | 0.00% | Add +345.3% | 22,266 | $13K |
| HRT Financial LP | 0.00% | Reduce -19.5% | 17,816 | $10K |
| Tandem Capital Management Corp. | 0.01% | No change | 15,500 | $9K |
| Hudson Bay Capital Management LP | 0.00% | New | 14,840 | $9K |
| Two Sigma Securities, LLC | 0.00% | New | 12,044 | $7K |
| UBS Group AG | 0.00% | Add +955100.0% | 9,552 | $5K |
| Bank of America Corp. | 0.00% | Add +5.4% | 428 | $246 |
| JPMorgan Chase & Co. | 0.00% | Reduce -7.5% | 184 | $106 |
| Bogart Wealth, LLC | 0.00% | No change | 60 | $34 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -49.0% | 25 | $14 |
"% of holder's portfolio" is UNICYCIVE THERAPEUTICS INC's weight in each manager's 13F, not the share of Unicycive Therapeutics Inc. the manager owns.